<DOC>
	<DOCNO>NCT00745901</DOCNO>
	<brief_summary>The purpose study healthy sexually active female evaluate cycle control norgestimate/ethinyl estradiol versus drospirenone/ethinyl estradiol .</brief_summary>
	<brief_title>Study Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol Drospirenone/Ethinyl Estradiol Healthy Sexually Active Females</brief_title>
	<detailed_description>This randomize , open-label , active-controlled , multicenter study healthy sexually active female evaluate cycle control norgestimate/ethinyl estradiol versus drospireneone/ethinyl estradiol . The Open-Label Treatment Phase last three 28-day cycle . Approximately 300 patient randomize 1:1 fashion accord predetermined randomization schedule . Patients see baseline visit ( Visit 1 ) 35 day prior dose obtain informed consent , physical examination include breast exam , height weight , vital sign , Chlamydia test urine pregnancy test perform , give medical history . Patients instructed report bleed data use interactive voice response system ( IVRS ) base diary daily basis . Patients instructed continue take 1 pill day 3 cycle , record information daily IVRS contact study site question adverse event would like discus . The final study visit ( Visit 2 ) occur Day 8 complete 3 cycle study medication . Patients weigh , vital sign perform , report adverse event change concomitant medication , complete satisfaction questionnaire final visit . Safety assess physical examination , adverse event , body weight vital sign . Patients randomize drospireneone/ethinyl estradiol take medication could increase serum potassium level ( outline Package Insert ) also potassium level check first cycle treatment ( Days 15 28 treatment ) . Three 28-day cycle either norgestimate/ethinyl estradiol drospirenone/ethinyl estradiol .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<criteria>Healthy female want oral contraception No cervical vaginal abnormality gynecological examination Negative Chlamydia test Pap smear without evidence moderate severe dysplasia malignancy within precede 12 month Negative urine pregnancy test conduct Visit 1 One normal menstrual period 35 day prior Visit 1 Regular menstrual cycle ( every 2635 day ) Last term pregnancy least 42 day prior Visit 1 , least one normal menstrual period ( typical duration amount flow subject ) since last pregnancy Postmenarcheal premenopausal At least one normal menstrual period ( typical duration amount flow subject ) since undergone uterines urgery removal IUD , Norplant , DepoProvera hormonal injectables implant . History presence disorder commonly accept contraindication steroid hormonal therapy Previously discontinue ORTHO TRICYCLEN LO YAZ due breakthrough bleed Pregnant lactate Body mass index ( BMI ) &gt; 40kg/m2 Clinical evidence carcinoma malignancy ( history basal cell carcinoma skin exclusionary ) History alcohol drug abuse investigator 's judgment base history physical examination ( within 12 month prior Visit 1 ) Significant depression psychiatric disease investigator 's judgment base history physical examination would result unreliable patient Patient deem investigator questionable reliability ability comply protocol provide accurate information Have medical condition plan surgical procedure , opinion investigator , may exacerbate treatment study medication patient receive concurrent therapy could affect treatment study medication Disallowed therapy : currently take therapeutic anticoagulant ( e.g , . Coumadin , Heparin ) bleed disorder ( e.g . von Willebrand 's Disease ) , DepoProvera hormonal injectables six month Visit 1 , currently Norplant hormonal implant place , removal Norplant within 60 day prior Visit 1 , use steroidcontaining IUD within 3 month prior Visit 1 Or current use IUD Consistently elevate blood pressure define sit systolic BP &gt; 140 mmHg diastolic BP &gt; 90 mmHg Have untreated thyroid disorder investigator 's judgment base history physical examination unable swallow solid , oral dosage form whole aid water ( participant may chew , divide , dissolve , crush study drug ) Patients opinion investigator enrol study base product label ORTHO TRICYCLEN LO YAZ include potential drugdrug interaction Have receive experimental drug use experimental medical device within 30 day plan start treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>contraception</keyword>
	<keyword>bleeding</keyword>
	<keyword>cycle control</keyword>
</DOC>